Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial
Services
Services
Date issued
2012Journal title
LANCET ONCOLOGY
Type of content
Artigo
